NeuroThera Labs Acquires Majority Stake in CliniQuantum to Advance Quantum-Powered Clinical Trials
Key Insights
NeuroThera Labs (search), a SciSparc subsidiary focused on CNS disorders, signed a definitive agreement to acquire 54.01% of CliniQuantum (search) for approximately $9.46 million in stock consideration.
CliniQuantum (search) develops quantum computing platforms to transform clinical trials by analyzing complex datasets for smarter, faster, and more adaptive study designs.
The acquisition includes potential earn-out payments up to $2.5 million based on patent filings and fundraising milestones over a three-year period.
NeuroThera Labs (search) Inc., a clinical-stage pharmaceutical company developing treatments for central nervous system disorders, has entered into a definitive share purchase agreement to acquire a majority stake in CliniQuantum (search) Ltd., a quantum technology company focused on revolutionizing clinical trials through quantum computing applications.
The transaction, announced March 10, 2026, will see NeuroThera acquire 56,375 shares representing approximately 54.01% of CliniQuantum (search)'s outstanding ordinary shares. SciSparc Ltd. (Nasdaq: SPRC) holds a controlling 75% interest in NeuroThera Labs (search).
Quantum Technology for Clinical Trial Innovation
CliniQuantum (search) operates as a quantum technology company holding patents from Ramot at Tel Aviv University in quantum simulation and quantum Monte Carlo methods. The company has developed a next-generation platform designed to transform clinical trials by harnessing quantum computing power to unlock insights from massive, complex datasets, enabling the design of smarter, faster, and more adaptive studies.
Transaction Structure and Valuation
Under the share purchase agreement, NeuroThera will issue 56,600,000 common shares as consideration for the acquired CliniQuantum (search) stake, representing an aggregate value of approximately $9,459,954.20. This valuation is based on the volume weighted average trading price of NeuroThera's common shares on the TSX Venture Exchange over the 20 trading days preceding the determination date.
The deal structure includes additional earn-out provisions potentially worth up to $2,500,000 in aggregate payments. These contingent payments, payable in cash and/or NeuroThera common shares at the company's discretion, are tied to specific milestones over a three-year earn-out period following transaction closure.
The earn-out structure includes $500,000 for each of the first three patent applications filed by CliniQuantum (search) with the United States Patent and Trademark Office or European Patent Office, capped at $1,500,000 total. Additionally, NeuroThera may pay an amount equal to 7.0% of any fundraising proceeds it raises, up to a maximum of $1,000,000.
Timeline and Regulatory Considerations
The transaction is expected to close within 30 days following submission of an application for Israeli tax ruling to the Israeli Tax Authority, subject to satisfaction or waiver of all closing conditions. The parties anticipate closing on or about March 31, 2026, unless otherwise agreed in writing.
Strategic Context for CNS Drug Development
NeuroThera Labs (search) focuses on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. Parent company SciSparc maintains a portfolio of cannabinoid pharmaceutical technologies, including SCI-110 for Tourette syndrome (search), Alzheimer's disease (search) and agitation treatment, and SCI-210 for autism spectrum disorder (search) and status epilepticus (search) treatment.
The acquisition of CliniQuantum (search)'s quantum computing capabilities could potentially enhance NeuroThera's clinical trial design and execution across its CNS-focused drug development pipeline, though specific integration plans were not detailed in the announcement.